Stock ALKS ALKERMES PLC
Add to a list
To use this feature you must be a member
Log inSign up

News Alkermes plc

Equities

ALKS

IE00B56GVS15

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-03 pm EDT 		5-day change 1st Jan Change
24.05 USD +0.80% Intraday chart for Alkermes plc -2.55% -13.30%
May. 02 UBS Adjusts Price Target on Alkermes to $21 From $23, Maintains Sell Rating MT
May. 01 Alkermes's Q1 Earnings, Revenue Grow But Miss Street View MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
UBS Adjusts Price Target on Alkermes to $21 From $23, Maintains Sell Rating
MT
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
PR
Alkermes : Q1 2024 Earnings Call Script FINAL 5 1 2024
PU
Alkermes : ALKS Q1 2024 Earnings Slides FINAL 5 1 2024
PU
Alkermes's Q1 Earnings, Revenue Grow But Miss Street View
MT
Transcript : Alkermes plc, Q1 2024 Earnings Call, May 01, 2024
Alkermes: Q1 Earnings Snapshot
AQ
Earnings Flash (ALKS) ALKERMES Reports Q1 Revenue $350.4M, vs. Street Est of $360.3M
MT
Earnings Flash (ALKS) ALKERMES Posts Q1 EPS $0.43, vs. Street Est of $0.58
MT
Alkermes plc Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Alkermes plc Reports First Quarter 2024 Financial Results
PR
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
PR
Alkermes to Report First Quarter Financial Results on May 1, 2024
PR
Alkermes Announces Positive Topline Results from Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients with Narcolepsy Type 2 and Idiopathic Hypersomnia
AQ
BlackBerry, Alkermes rise; Neogen, Tilray Brands fall, Tuesday, 4/9/2024
AQ
Sector Update: Health Care Stocks Edge Higher Pre-Bell Tuesday
MT
Alkermes Says Potential Narcolepsy Drug Improves Wakefulness in Phase 1b Study
MT
Alkermes plc Announces Positive Topline Results from Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients with Narcolepsy Type 2 and Idiopathic Hypersomnia
CI
Alkermes Insider Sold Shares Worth $292,740, According to a Recent SEC Filing
MT
Baird Initiates Alkermes With Outperform Rating, Price Target is $37
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALKS Stock
  4. News Alkermes plc